Prosecution Insights
Last updated: April 19, 2026

Examiner: LEESER, ERICH A

Tech Center 1600 • Art Units: 1622 1624

This examiner grants 82% of resolved cases

Performance Statistics

81.5%
Allow Rate
+21.5% vs TC avg
963
Total Applications
+13.5%
Interview Lift
829
Avg Prosecution Days
Based on 948 resolved cases, 2023–2026

Rejection Statute Breakdown

1.4%
§101 Eligibility
22.0%
§102 Novelty
12.7%
§103 Obviousness
38.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18549288 METHODS AND COMPOSITIONS FOR TREATMENT OF LOW CIRCULATING TESTOSTERONE CONDITIONS Non-Final OA University of Florida Research Foundation, Inc.
17949188 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT Non-Final OA H. Lundbeck A/S
18549158 Treatment of Breast Cancer with Amcenestrant and Palbociclib Non-Final OA Pfizer Inc.
18537700 INHIBITORS OF CANCER INVASION, ATTACHMENT, AND/OR METASTASIS Non-Final OA Sanford Burnham Prebys Medical Discovery Institute
18579114 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY Non-Final OA NURIX THERAPEUTICS, INC.
18488248 STEVIA COMPOSITION Non-Final OA PURECIRCLE SDN BHD
18259532 REAGENT AND METHOD FOR TREATING SKIN DISEASES OR CONDITIONS ASSOCIATED WITH ANTI-TUMOR AGENT Non-Final OA ONQUALITY PHARMACEUTICALS CHINA LTD.
18558166 PROCESS FOR THE PREPARATION OF ANTIBACTERIAL COMPOUNDS Non-Final OA DISCUVA LIMITED
18288195 A SOLID STATE FORM OF TAFAMIDIS AND A PROCESS FOR ITS PREPARATION Non-Final OA Quimica Sintetica, S.A.
18273011 IMIDAZOLOPYRIDAZINE OR PYRAZOLOPYRIMIDINE COMPOUNDS AND COMPOSITIONS Non-Final OA Anrui Biomedical Technology (Guangzhou) Co., Ltd.
18043883 SULPHAMOYL UREA DERIVATIVES CONTAINING ALKYL-OXACYCLOALKYL MOIETY AND USES THEREOF Non-Final OA NodThera Limited
18020761 METHODS OF TREATING GOUT Non-Final OA Horizon Therapeutics USA, Inc.
17925003 FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS Non-Final OA GLIXOGEN THERAPEUTICS LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month